Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002519 · ClinicalTrials.gov registry record · Phase 1
Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation
A Phase 1 study, sponsored by Pluristem.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03002519 is a Phase 1 study that has completed, run by Pluristem. The registered enrollment target is 21 participants.
The verdict
NCT03002519, a Phase 1 study, has completed, sponsored by Pluristem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study aims to evaluate the safety of intramuscular (IM) administration of PLX-R18 in subjects with incomplete hematopoietic recovery following HCT.
Interventions
- BIOLOGICAL PLX-R18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-02-08 |
| Est. Completion | 2021-10-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002519
The ClinicalTrials.gov registry entry for NCT03002519 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pluristem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PLX-R18 is the first listed.
NCT03002519 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002519 about?
NCT03002519 is a clinical study titled "Safety Evaluation of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation". This study aims to evaluate the safety of intramuscular (IM) administration of PLX-R18 in subjects with incomplete hematopoietic recovery following HCT.
What is the current status of trial NCT03002519?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-02-08. Estimated completion is 2021-10-30.
What interventions are being tested in trial NCT03002519?
The interventions under investigation include: PLX-R18 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03002519?
This trial is sponsored by Pluristem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.